BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wong KM, King GG, Harris WP. The Treatment Landscape of Advanced Hepatocellular Carcinoma. Curr Oncol Rep. [DOI: 10.1007/s11912-022-01247-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Rizzo A, Ricci AD. Challenges and Future Trends of Hepatocellular Carcinoma Immunotherapy. IJMS 2022;23:11363. [DOI: 10.3390/ijms231911363] [Reference Citation Analysis]
2 Xue JN, Wang YY, Wang YC, Zhang N, Zhang LH, Lu ZH, Zhao LJ, Zhao HT. Novel cellular therapies for hepatobiliary malignancies. Hepatobiliary Pancreat Dis Int 2022:S1499-3872(22)00200-4. [PMID: 36100543 DOI: 10.1016/j.hbpd.2022.08.014] [Reference Citation Analysis]
3 Thuru X, Magnez R, El-bouazzati H, Vergoten G, Quesnel B, Bailly C. Drug Repurposing to Enhance Antitumor Response to PD-1/PD-L1 Immune Checkpoint Inhibitors. Cancers 2022;14:3368. [DOI: 10.3390/cancers14143368] [Reference Citation Analysis]
4 Sauzeau V, Beignet J, Vergoten G, Bailly C. Overexpressed or hyperactivated Rac1 as a target to treat hepatocellular carcinoma. Pharmacol Res 2022;:106220. [PMID: 35405309 DOI: 10.1016/j.phrs.2022.106220] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]